Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Federal Trade Commission
Boehringer Ingelheim
Fuji
QuintilesIMS
Citi

Generated: August 26, 2019

DrugPatentWatch Database Preview

Litigation Details for TEVA PHARMACEUTICALS USA, INC. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2014)

  Try a free trial


See Plans and Pricing

« Back to Dashboard

TEVA PHARMACEUTICALS USA, INC. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2014)

Docket ➤ Sign Up Date Filed 2014-10-07
Court District Court, N.D. West Virginia Date Terminated
Cause 35:271 Patent Infringement Assigned To Irene Patricia Murphy Keeley
Jury Demand None Referred To
Parties MYLAN INC.; MYLAN PHARMACEUTICALS INC.; NATCO PHARMA LTD.; TEVA NEUROSCIENCE, INC.; TEVA PHARMACEUTICAL INDUSTRIES, LTD.; TEVA PHARMACEUTICALS USA, INC.; YEDA RESEARCH AND DEVELOPMENT CO.,LTD.
Patents 8,232,250; 8,399,413
Attorneys Crystal R. Canterbury; Daryl L. Wiesen; David L. Anstaett; David M. Hashmall; Elizabeth J. Holland; Gordon H. Copland; James F. Companion; John T. Bennett; Nicholas K. Mitrokostas; Shannon M Bloodworth; William G. James; William J O'Brien; Yolonda G. Lambert
Link to Docket External link to docket
Small Molecule Drugs cited in TEVA PHARMACEUTICALS USA, INC. v. Mylan Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is ➤ Sign Up .

Details for TEVA PHARMACEUTICALS USA, INC. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-10-07 1 of United States Patent No. 8,232,250 (“the ’250 patent”) and United States Patent No. 8,399,413 (“the… #: 11 COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 8,232,250 BY DEFENDANTS 69. The allegations of the…DECLARATORY JUDGMENT OF INFRINGMENT OF U.S. PATENT NO. 8.232.250 BY DEFENDANTS 84. The allegations of the…copy of the ’250 patent is attached as Exhibit A. The ’413 Patent 53. The ’413 patent, entitled “Low … ’413 patent. 56. Teva Ltd. is the exclusive licensee of the ’413 patent. 57. The ’413 patent is listed External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Medtronic
Chubb
Queensland Health
Healthtrust
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.